Original Article
Oncogene (2009) 28, 709–720; doi:10.1038/onc.2008.423; published online 24 November 2008
Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells
X Sui1,2, S Shin1,2,3, R Zhang1, P F Firozi1,4, L Yang1,5, J L Abbruzzese1 and S A G Reddy1
1Department of Gastrointestinal Medical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA
Correspondence: Dr SAG Reddy, Department of Gastrointestinal Medical Oncology, Unit 426, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Blvd., Houston, TX 77030, USA. E-mail: sa08366@odin.mdacc.tmc.edu
2These authors contributed equally to this work.
3Current address: Department of Internal Medicine, East Tennessee State University, Johnson City, TN 37614-70622, USA.
4Current address: Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA.
5Current address: Department of Biology and Biochemistry, University of Houston, Houston, TX 77204, USA.
Received 7 May 2008; Revised 19 September 2008; Accepted 15 October 2008; Published online 24 November 2008.
Abstract
There is emerging evidence that the oncogenic potential of hdm2 (human and/or murine double minute-2 protein) stems not only from its ability to counteract tumor suppressor p53 but also from its less understood p53-independent functions. Surprisingly, little is known about the role and regulation of hdm2 in pancreatic tumors, a large proportion (50–75%) of which contain mutant p53. In this study, we determined that hdm2 was expressed in a Ras-signaling-dependent manner in various pancreatic cancer cell lines. As p53 was mutated and inactive in these cells, the expression of hdm2 was seemingly redundant. Indeed, the proliferation and survival of cell lines such as Panc-1 and Panc-28 could be inhibited by PRIMA-1 (mutant p53 activator) but not by Nutlin-3 (inhibitor of the hdm2–p53 interaction). Unexpectedly, however, the proliferation of both cell lines was strongly inhibited by hdm2-specific RNAi. Our data also revealed cyclin D1, c-Jun and c-Myc to be novel targets of hdm2 and suggested that they might mediate hdm2's role in cellular proliferation and/or survival. We conclude from our results that hdm2 is expressed in pancreatic cancer cells as a result of activated Ras signaling, and that it regulates cellular proliferation and the expression of three novel target genes by p53-independent mechanisms.
Keywords:
pancreatic cancer, hdm2, K-Ras, c-Jun, cyclin D1, c-Myc
Abbreviations:
hdm2, human and/or murine double minute-2 protein; MEK, mitogen and extracellular signal-regulated protein kinase; p53, tumor suppressor p53
MORE ARTICLES LIKE THIS
These links to content published by NPG are automatically generated
REVIEWS
Immunoregulatory functions of mTOR inhibition
Nature Reviews Immunology Review (01 May 2009)
RNAi-mediated knockdown of target genes: a promising strategy for pancreatic cancer research
Cancer Gene Therapy Review
RESEARCH
Nature Genetics Article (01 Sep 1999)
Kidney International Original Article
Ras isoform abundance and signalling in human cancer cell lines
Oncogene Original Article
